Minerva Neurosciences reported $0 in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Adma Biologics USD 124.4M 9.9M Jun/2026
ALKERMES USD 480.13M 15.88M Sep/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
AstraZeneca USD 16.21B 830M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cipla INR 74.04B 2.85B Sep/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 2.6M 3.75M Jun/2026
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 24.4B 1.43B Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
J&J USD 25.4B 89M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 16.6B 1.57B Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 14.44B 2.49B Sep/2026
Takeda JPY 1.19T 32.9B Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024